Antimetabolites: Established cancer therapy

Journal of Cancer Research and Therapeutics

Volumn 8, Issue 4, 2012, Pages 510-519

  Tiwari, Manjul ^a  

^a SHARDA UNIVERSITY   (India)

Author keywords

Antimetabolites; apoptosis; cell death; mitotic catastrophe; necrosis

Indexed keywords

ANTIMETABOLITE; AZACITIDINE; BGC 9331; CAPECITABINE; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLOXURIDINE; FLUDARABINE; FLUOROURACIL; PENTOSTATIN; PLEVITREXED; RALTITREXED; RAPAMYCIN; TAMOXIFEN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VINBLASTINE;

ANOIKIS; APOPTOSIS; AUTOPHAGY; CANCER CHEMOTHERAPY; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL DEATH; CELL DIFFERENTIATION; COLORECTAL CANCER; HUMAN; MITOSIS; REVIEW; SENESCENCE; TREATMENT RESPONSE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL AGING; DNA DAMAGE; HUMANS; MITOSIS; NECROSIS; NEOPLASMS;

EID: 84875538623     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.106526     Document Type: Review

References (149)

1. Castro-Obregon S, Rao RV, del Rio G, Chen SF, Poksay KS, Rabizadeh S, et al. Alternative, nonapoptotic programmed cell death. J Biol Chem 2004;279:17543-53.
2. Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999;59:1391-9.
3. Tannock IF, Lee C. Evidence against apoptosis as a major mechanism for reproductive cell death following treatment of cell lines with anti-cancer drugs. Br J Cancer 2001;84:100-5.
4. Brown M, Wilson G. Apoptosis genes and resistance to cancer therapy. Cancer Biol Ther 2003;2:477-90.
5. Gudkov A, Komarova EA. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 2003;3:117-29.
6. Green DR, McGahon A, Martin SJ. Regulation of apoptosis by oncogenes. J Cell Biochem 1996;60:33-8.
7. Gajewski TF, Thompson CB. Apoptosis meets signal transduction: Elimination of a BAD influence. Cell 1996;87:589-92.
8. Sobrero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer- A tale of two drugs: Implications for biochemical modulation. J Clin Oncol 1997;15:368-81.
9. van Laar JA, Rustum YM, Ackland SP, van Groeningen CJ, Peters GJ. Comparison of 5-fluoro-2?-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. Eur J Cancer1998;34:296-306.
10. Schwartzberg L, Petak I, Stewart C, Turner PK, Ashley J, Tillman DM, et al. Modulation of the Fas signaling pathway by interferon-in therapy of colon cancer: Phase I trial and correlative studies of interferon, 5-fluorouracil andleucovorin. Clin Cancer Res 2002;8:2488-98.
11. Houghton JA, Tillman DM, Harwood FG. The ratio of dATP/dTTP influences the commitment ofhuman colon carcinoma cells to thymineless death. Clin Cancer Res 1995;1:723-30.
12. Maybaum J, Ullman B, Mandel HG, Day JL, Sadee W. Regulation of RNA-and DNA-directedactions of 5-fluoropyrimidines in mouse T-lymphoma (S-49) cells. Cancer Res 1980;40:4209-15.
13. Petak I, Tillman DM, Houghton JA. P53-dependence of Fas induction and acute apoptosis inresponse to 5-fluorouracil-leucovorin in human colon carcinoma cell lines. Clin Cancer Res 2000;6:4432-41.
14. Parsels LA, Parsels JD, Wagner LM, Loney TL, Radany EH, Maybaum J. Mechanism and pharmacological specificity of dUTPase-mediated protection from DNA damage and cytotoxicity in human tumor cells. Cancer Chemother Pharmacol 1998;42:357-62.
15. Grem JL. 5-Fluorouracil: Forty plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 2000;18:299-313.
16. Houghton JA, Houghton PJ, Wooten RS. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine and 5-fluoro-2?-deoxyuridine. Cancer Res 1979;39:2406-13.
17. Pritchard DM, Watson AJM, Potten CS. Jackman AL, Hickman JA. Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: Evidence for the involvement of RNA perturbation. Proc Natl Acad Sci USA 1997;94:1795-9.
18. Rustum YM, Cao S. New drugs in colorectal cancer: Preclinical studies. Semin Oncol 1999;26:612-20.
19. Sobrero A, Guglielmi A, Grossi F, Puglisi F, Aschele C. Mechanism of action of fluoropyrimidines: Elevance to the new developments in colorectal cancer chemotherapy. Semin Oncol 2000;27(5 Suppl 10):72-7.
20. Geller JI, Szekely-Szucs K, Petak I, Doyle B, Houghton JA. P21Cip1 is a critical mediator of the cytotoxic action of thymidylate synthase (TS) inhibitors in colorectal carcinoma cells. Cancer Res 2004;64:6296-303.
21. Eisold S, Linnebacher M, Ryschich E, Antolovic D, Hinz U, Klar E, et al. The effect of adenovirus expressing wild-type p53 on 5-fluorouracil chemosensitivity is related to p53 status in pancreatic cancer cell lines. World J Gastroenterol 2004;10:3583-9.
22. de Angelis PM, Fjell B, Kravik KL, Haug T, Tunheim SH, Reichelt W, et al. Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil. Int J Oncol 2004;24:1279-88.
23. Li WW, Fan J, Hochhauser D, Bertino JR. Overexpressioin of p21waf1 leads to increased inhibition of E2F-1 phosphorylation and sensitivity to anticancer drugs in retinoblastoma-negative human sarcoma cells. Cancer Res 1997;57:2193-9.
24. Parsels LA, Parsels JD, Tai DC-H, Coughlin DJ, Maybaum J. 5-Fluoro-2-deoxyuridine-induced cdc25A accumulation correlates with premature mitotic entry and clonogenic death in human colon cancer cells. Cancer Res 2004;64:6588-94.
25. Xiao Z, Xue J, Sowin TJ, Rosenberg SH, Zhang H. A novel mechanism of checkpoint abrogation conferred by chk1 downregulation. Oncogene 2005;24:1403-11.
26. Engels IH, Stepczynska A, Stroh C, Lauber K, Berg C, Schwenzer R, et al. Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis. Oncogene 2000;19:4563-73.
27. Adachi Y, Taketani S, Oyaizu H, Ikebukuro K, Tokunaga R, Ikehara S. Apoptosis of colorectal adenocarcinoma induced by 5-FU and/or IFNgamma through caspase 3 and caspase 8. Int J Oncol 1999;15:1191-6.
28. Wu XX, Kakehi Y, Mizutani Y, Lu J, Terachi T, Ogawa O. Activation of caspase-3 in renal cell carcinoma cells by anthracyclines or 5-fluorouracil. Int J Oncol 2001;19:19-24.
29. Petak I, Tillman DM, Harwood FG, Houghton JA. Fas-dependent and-independent mechanisms of cell death following DNA damage in human colon carcinoma cells. Cancer Res 2000;60:2643-50.
30. Peters GJ, van Triest B, Backus HH, Kuiper CM, van der Wilt CL, Pinedo HM. Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor ralitrexed. Eur J Cancer 2000;36:916-24.
31. Geller J, Petak I, Szekely Szucs K, Nagy K, Tillman DM, Houghton JA. Interferon-induced sensitization of colon carcinomas to ZD9331 targets caspases, downstream of Fas, independent of mitochondrial signaling and the IAP survivin. Clin Cancer Res 2003;9:6504-15.
32. Green DR, Beere HM. Killers or clean-up crew: How central are the central mechanisms of apoptosis. In: Hickman JA, Dive C, editors. Apoptosis and cancer therapy. Totowa, NJ: Humana PressInc.; 1999. p. 157-74.
33. McCarthy NJ, Whyte MK, Gilbert CS, Evan GI. Inhibition of ced-3/ICErelated proteases doesnot prevent cell death induced by oncogenes, DNA damage, or the Bcl-2 homologue Bak. J Cell Biol 1997;136:215-27.
34. Houghton JA, Harwood FG, Tillman DM. Thymineless death in colon carcinoma cells is mediatedvia Fas signaling. Proc Natl Acad Sci USA 1997;94:8144-9.
35. Tillman DM, Petak I, Houghton JA. A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells. Clin Cancer Res 1999;5:425-30.
36. Eichhorst ST, Muller M, Li-Weber M, Schulze-Bergkamen H, Angel P, Krammer PH. A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs. Mol Cell Biol 2000;20:7826-37.
37. Longley DB, Allen WL, McDermott U, Wilson TR, LAtif T, Boyer J, et al. The roles of thymidylate synthase and p53 in regulating Fasmediated apoptosis in response to antimetabolites. Clin Cancer Res 2004;10:3562-71.
38. Eichhorst ST, Muerkoster S, Weigand MA, Krammer PH. The chemotherapeutic drug 5-fluorouracil induces apoptosis in mouse thymocytes in vivo via activation of the CD95(APO-1/Fas) system. Cancer Res 2001;61:243-48.
39. Ciccolini J, Fina F, Bezulier K, Giacometti S, Roussel M, Evrard A, et al. Transmission of apoptosis in human colorectal tumor cells exposed to capecitabine, xeloda, is mediated via Fas. Mol Cancer Ther 2002;1:923-7.
40. Moller P, Koretz K, Leithauser F, Bruderlein S, Henne C, Quentmeier A, et al. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer 1994;57:371-7.
41. Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Henne C, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993;69:415-29.
42. Iwase M, Watanabe H, kondo G, Ohashi M, Nagumo M. Enhanced susceptibility of oral squamous cell carcinoma cell lines to FASmediated apoptosis by cisplatin and 5-fluorouracil. Int J Cancer 2003;106:619-25.
43. Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC, et al. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitization of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 2004;11:S86-96.
44. Lacour S, Micheau O, Hammann A, Drouineaud V, Tschopp J, Solary E, et al. Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells. Oncogene 2003;22:1807-16.
45. Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res 2002;62:5800-6.
46. Yamamoto T, Nagano H, Sakon M, Wada H, Eguchi H, Kondo M, et al. Partial contribution of tumor necrosis factor-related apootosisinducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5- fluorouracil against hepatocellular carcinoma. Clin Cancer Res 2004;10:7884-95.
47. Wang S, El-Deiry WS. Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Res 2004;64:6666-72.
48. Wang W, Cassidy J. Constitutive nuclear factor-kappa B m RNA, protein overexpression and enhanced DNA-binding activity in thymidylaye synthase inhibitor-resistant tumour cells. Br J Cancer 2003;88:624-9.
49. Wang W, McLeod HL, Cassidy J. Disulfiram-mediated inhibition of NF-B activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer 2003;104:504-11.
50. Voboril R, Hochwald SN, Li J, Brank A, Weberova J, Wessels F, et al. Inhibition of NF-kappa B augments sensitivity to 5-fluorouracil/folinic acid in colon cancer. J Surg Res 2004;120:178-88.
51. Uetsuka H, Haisa M, Kimura M, Gunduz M, Kaneda Y, Ohkawa T, et al. Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line. Exp Cell Res 2003;10:27-35.
52. Yang JH, Fenf F, Qian H, Cheng H. Chemosensitization of breast carcinoma cells with the use of bcl-2 antisense oligonucleotide. Breast 2004;13:227-31.
53. Guo B, Cao S, Toth K, Azrak RG, Rustum YM. Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma. Clin Cancer Res 2000;6:718-24.
54. Xu ZW, Freiss H, Buchler MW, Solioz M. Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents. Cancer Chemother Pharmacol 2002;49:504-10.
55. Pritchard DM, Print C, O'Reilly L, Adams JM, Potten CS, Hickman JA. Bcl-w is an important determinant of damage-induced apoptosis in epithelia of small and large intestine. Oncogene 2000;19:3955-9.
56. Yuan J, Yanker BA. Caspase activity sows the seeds of neuronal death. Nat Cell Biol 1999;1:E44-5.
57. Rao RV, Castro-Obregon S, Frankowski H, Schuler M, Stoka V, Del Rio G, et al. Coupling endoplasmic reticulum stress to the cell death program. An Apaf-1-independent intrinsic pathway. J Biol Chem 2002;277:21836-42.
58. Morishima N, Nakanishi K, Takenouchi H, Shibata T, Yasuhiko Y. An endoplasmic reticulum stress-specific caspase cascade in apoptosis. Cytochrome c-independent activation of caspase-9 by caspase-12. J Biol Chem 2002;277:34287-94.
59. Halloran CM, Ghaneh P, Shore S, Greenhalf W, Zumstein L, Wilson D, et al. %-Fluorouracil or gemcitabine combined with adenoviralmediated reintroduction of p16INK4A greatly enhanced cytotoxicityt in Panc-1 pancreatic adenocarcinoma cells. J Gene Med 2004;6:514-25.
60. Hsu LC, Lee RM, White RL. The HPV16 E6/E7 oncogene sensitizes human ovarian surface epithelial cells to low-dose but not high-dose 5-FU and 5-FUdR. Biochem Biophys Res Commun 2004;320:249-55.
61. Elliott MJ, Farmer MR, Atienza C, Stilwell A, Dong YB, Yang HL, et al. E2F-1 gene therapy induces apoptosis and increases chemosensitivity in human pancreatic carcinoma cells. Tumour Biol 2002;23:76-86.
62. Ramsay RG, Micallef S, Lightowler S, Mucenski ML, Mantamadiotis T, Bertoncello I. C-myb heterozygous mice are hypersensitive to 5-fluorouracil and ionizing radiation. Mol Cancer Res 2004;2:354-61.
63. Modrak DE, Rodriguez MD, Goldenberg DM, Lew W, Blumenthal RD. Sphingomyelin enhances chemotherapy efficacy and increases apoptosis in human colonic tumor xenografts. Int J Oncol 2002;20:379-84.
64. Tseng YS, Tzeng CC, Chiu AW, Lin CH, Won SJ, Wu IC, et al. Haras overexpression mediated cell apoptosis in the presence of 5-fluorouracil. Exp Cell Res 2003;288:403-14.
65. Jin W, Wu L, Liang K, Liu B, Lu Y, Fan Z. Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells. Br J Cancer 2003;89:185-91.
66. Sun Y, Tang XM, Half E, Kuo MT, Sinicrope FA. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res 2002;62:6323-8.
67. Chen WS, Liu JH, Liu JM, Lin JK. Sequence-dependent effect of a cyclooxygenase-2 inhibitor on topoisomerase I inhibitor and 5-fluorouracil- induced cytotoxicity of colon cancer cells. Anticancer Drugs 2004;15:287-94.
68. Meyers M, Wagner MW, Hwang H-S, Kinsella TJ, Boothman DA. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 2001;61:5193-201.
69. Meyers M, Hwang A, Wagner MW, Boothman DA. Special section: Impact of the environment on colon cancer (II): Roles of DNA mismatch repair in apoptotic responses to therapeutic agents. Environ Mol Mutagen 2004;44:249-64.
70. Schneider HJ, Sampson SA, Cunningham D, Norman AR, Andreyev HJ, Tilsed JV, et al. Bcl-2 expression and response to chemotherapy in colorectal adenocarcinomas. Br J Cancer 1997;75:427-31.
71. Paradiso A, Simone G, Lena MD, Leone B, Vallejo C, Lacava J, et al. Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer. Br J Cancer 2001;84:651-8.
72. Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997;275:967-9.
73. Ouyang H, Furukawa T, Abe T, Kato Y, Horii A. The BAX gene, the promoter of apoptosis, is mutated in genetically unstable cancers of the colorectum, stomach, and endometrium. Clin Cancer Res 1998;4:1071-4.
74. Ionov Y, Yamamoto H, Krajewski S, Reed JC, Perucho M. Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc Natl Acad Sci USA 2000;97:10872-7.
75. Schelwies K, Sturm I, Grabowski P, Scherubl H, Schindler I, Hermann S, et al. Analysis of P53/BAX in primary colorectal carcinoma: Low BAX protein expression is a negative prognostic factor in UICC stage III tumors. Int J Cancer 2002;99:589-96.
76. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-9.
77. Sturm I, Kohne C-H, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, et al. Analysis of the p53/BAX pathway in colorectal cancer: Low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol 1999;17:1364-74.
78. Sarela A, Scott N, Ramsdale J, Markham AF, Guilou PJ. Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage II colorectal carcinomas. Ann Surg Oncol 2001;8:305-10.
79. Rodel F, Hoffmann J, Grabenbauer GG, Papadopoulos T, Weiss C, Gunther K, et al. High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol 2002;178:426-35.
80. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998;58:5071-4.
81. Takamizawa S, Scott D, Wen J, Grundy P, Bishop W, Kimura K, et al. The survivin:fas ratio in pediatric renal tumors. J Pediatr Surg 2001;36:37-42.
82. Sandler A, Scott D, Azuhata T, Takamizawa S, O'Dorisio S. The survivin:Fas ratio is predictive of recurrent disease in neuroblastoma. J Pediatr Surg 2002;37:507-11.
83. Olie RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stahel RA, et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cells to chemotherapy. Cancer Res 2000;60:2805-9.
84. Kufe D, Spriggs D, Egan EM, Munroe D. Relationships among Ara-CTP pools, formation of (Ara-C) DNA, and cytotoxicity of human leukemic cells. Blood 1984;64;54-8.
85. Mansson E, Paul A, Lofgren C, Ullberg K, Paul C, Eriksson S, et al. Cross-resistance to cytosine arabinoside in a multidrug-resistant human promyelocytic cell line selected for resistance to doxorubicin: Implications for combination chemotherapy. Br J Haematol 2001:114:557-65.
86. Aciwa H, Oguri T, Sato S, Maeda H, Niimi T, Ueda R. Determinants of sensitivity and resistance to gemcitabine: The roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci 2004;95:753-7.
87. Galmarini CM, Clrke ML, Jordheim L, Santos CL, Cros E, Mackey JR, et al. Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. BMC Pharmacol 2004;4:8.
88. Duxbury MS, Hiromichi I, Zinner MJ, Ashley SW, Whang EE. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 2004;23:1539-48.
89. Kanno S, Higurashi A, Watanabe Y, Shouji A, Asou K, Ishikawa M. Susceptibility to cytosine arabinoside (Ara-C)-induced cytotoxicity in human leukemia cell lines. Toxicol Lett 2004;152:149-58.
90. Chen M, Hough AM, Lawrence TS. The role of p53 in gemcitabinemediated cytotoxicity and radio sensitization. Cancer Chemother Pharmacol 2000;45:369-74.
91. Schniewind B, Christgen M, Kurdow R, Haye S, Kremer B, Kalthoff H. Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. Int J Cancer 2004;109:182-8.
92. Wang Z, Wang S, Dai Y, Grant S. Brostatin 1 increases 1-beta-D-arabinofuranosylcytosine-induced cytochrome c release and apoptosis in human leukemia cells ectopically expressing Bcl-xL. J Pharmacol Exp Ther 2002;301:568-77.
93. Tang L, Boise LH, Dent P, Grant S. Potentiation of 1-beta- Darabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing Bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01). Biochem Pharmacol 2000;60:1445-56.
94. Kim CN, Wang X, Huang Y, Ibrado AM, Liu L, Fang G, et al. Overexpression of Bcl-x(L) inhibits Ara-C-induced mitochondrial loss of cytochrome c and other perturbations that activate the molecular cascade of apoptosis. Cancer Res 1997;57:3115-20.
95. Chang GC, Hsu SL, Tsai JR, Wu WJ, Chen CY, Sheu GT. Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. Eur J Pharmacol 2004;502:169-83.
96. Xu Z, Freiss H, Solioz M, Aebi S, Korc M, Kleef J, et al. Bcl-x(L) antisense oligonucleotides induce apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabine. Int J Cancer 2001;94:268-74.
97. Konopleva M, Tari AM, Estrov Z, Harris D, Xie Z, Zhao S, et al. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood 2001;95:3929-38.
98. Vrana JA, Bieszczad CK, Cleveland ES, Ma Y, Park JP, Mohandas TK, et al. An MCL-1-overexpressing Burkitt lymphoma subline exhibits enhanced survival on nexpopsure to serum deprivation, topoisomerase inhibitors, or staurosporine but remains sensitive to 1-beta-D-arabinofuranosylcytosine. Cancer Res 2002;62:892-900.
99. Shi X, Liu S, Kleeff J, Freiss H, Buchler MW. Acquired resistance of pancreatic cancer cells towards 5-fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 2002;62:354-62.
100. Lock RB, Stribinskene L. Dual modes of cell death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. Cancer Res 1996;56:4006-12.
101. Amarante-Mendes GP, Finucane DM, Martin SJ, Cotter TG, Salvesen GS, Green DR. Anti-apoptotic oncogenes prevent caspase-dependent and independent commitment for cell death. Cell Death Differ 1998;4:298-306.
102. Ng SS, Tsao MS, Chow S, Hadley DW. Inhibition of phosphatidylinositide 3-kinase enhances gencitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 2000;60:5451-5.
103. Ng SS, Tsao MS, Nicklee T, Hedley DW. Wortmannin inhibits pkb/akt phosphorylation and promotes gencitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res 2001;7:3269-75.
104. Yokoi K, Fidler IJ. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin Cancer Res 2004;10:2299-306.
105. Yu C, Wang Z, Dent P, Grant S. MEK1/2 inhibitors promote Ara-Cinduced apoptosis but not loss in m in HL-60 cells. Biochem Biophys Res Commun 2001;286:1011-8.
106. Milella M, Kornblau SM, Estrov Z, Carter BZ, Lapillonne H, Harris D, et al. Therapeutic targeting of the MEKK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 2001;108:851-9.
107. Habiro A, Tanno S, Koizumi K, Izawa T, Nakano Y, Osanai M, et al. Involvement of p38 mitogen-activated protein kinase in gemcitabineinduced apoptosis in human pancreatic cancer cells. Biochem Biophys Res Commun 2004;316:71-7.
108. Jarvis WD, Fornari FA, Tombes RM, Erukulla RK, Bittman R, Schwartz GK, et al. Evidence of involvement of mitogen-activated protein kinase, rather than stress-activated protein kinase, in potentiation of 1-D- arabinofuranosylcytosine-induced apoptosis by interruption of protein kinase C signaling. Mol Pharmacol 1998;54:844-56.
109. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. Inhibition of Src tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res 2004;10:2307-18.
110. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. SiRNA directed against s-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity. J Am Coll Surg 2004;198:953-9.
111. Arlt A, Gehrz A, Muerkoster S, Vorndamm J, Kruse ML, Folsch UR, et al. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003;22:3243-51.
112. Jones DR, Broad RM, Comeau LD, Parsons SJ, Mayo MW. Inhibition of nuclear factor kappaB chemosensitizes non-small cell lung cancer through cytochrome c release and caspase activation. J Thorac Cardiovasc Surg 2002;123:310-7.
113. Romano MF, Lamberti A, Bisogni R, Tassone P, Pagnini D, Storti G, et al. Enhancement of cytosine arabinoside-induced apoptosis in human myeloblastic leukemia cells by NF-kappa B-Rel-specific decoy oligodeoxynucleotides. Gene Ther 2000;7:1234-7.
114. Denlinger CE, Rundall BK, Keller MD, Jones DR. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. Ann Thorac Surg 2004;78:1207-14.
115. Zheng B, Georgakis GV, Li Y, Bharti A, McConkey D, Aggarwal BB, et al. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-B mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res 2004;10:3207-15.
116. Kamat AM, Karashima T, Davis DW, Lashinger L, Bar-Eli M, Millikan R, et al. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther 2004;3:279-90.
117. Meli M, Tolomeo M, D'Alessandro N, Grimaudo S, Notarbartolo M, Papoff G, et al. Resiatance to gemcitabine in a lymphoma cell line resistant to Fas-mediated apoptosis. Anticancer Res 2004;24:851-7.
118. Ferreira CG, Tolis C, Span SW, Peters GJ, van Lopik T, Kummer AJ, et al. Drug-induced apoptosis in lung cancer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway. Clin Cancer Res 2000;6:203-12.
119. Liu W, Bodle E, Chen JY, Gao M, Rosen GD, Broaddus VC. Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines. Am J Respir Cell Mol Biol 2001;25:111-8.
120. Fojo T, Bates S. Strategies for reversing drug resistance. Oncogene 2003;22:7512-23.
121. Glover AB, Leyland-Jones BR, Chun HG, Davies B, Hoth DF. Acacitidine: 10 years later. Cancer Treat Rep 1987;71:737-46.
122. Momparler RL, Cote S, Eliopoulos N. Pharmacological approach for optimization of the dose schedule of 5-aza-2-deoxycytidine (decitabine) for the therapy of leukemia. Leukemia 1997;11:175-80.
123. Durant ST, Morris MM, Illand M, McKay HJ, McCormick C, Hirst GL, et al. Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes. Curr Biol 1999;9:51-4.
124. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2-deoxy-5-azacytidineinduced demethylation of the hMLH1 gene promoter. Cancer Res 2000;60:6039-44.
125. Strathdee G, MacKean MJ, Illand M, Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 1999;18:2335-41.
126. Teitz T, Lahti JM, Kidd VJ. Aggressive childhood neuroblastomas do not express caspase-8: An important component of programmed cell death. J Mol Med (Berl) 2001;79:428-36.
127. Eggert A, Grotzer MA, Zuzak TJ, Wiewrodt BR, Ho R, Ikegaki N, et al. Resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res 2001;61:1314-9.
128. Hopkins-Donaldson S, Bodmer J-L, Bourland KB, Brognara CB, Tschopp J, Gross N. Loss of caspase-8 expression in neuroblastoma is related to malignancy and resistance to TRAIL-induced apoptosis. Med Pediatr Oncol 2000;35:608-11.
129. Fulda S, Kufer MU, Meyer E, van Halen F, Dockhorn-Dworniczak B, Debatin K-M. Sensitization for death receptor-or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001;20:5865-77.
130. Grotzer MA, Eggert A, Zuzak TJ, Janss AJ, Marwaha S, Wiewrodt BR, et al. Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Oncogene 2000;19:4604-10.
131. Gomyo Y, Sasaki J, Branch C, Roth JA, Mukhopadhyay T. 5-Aza-2-deoxycytidine upregulates caspase-9 expression cooperating with p53-induced apoptosis in human lung cancer cells. Oncogene 2004;23:6779-87.
132. Ueki T, Takeuchi T, Nishimatsu H, Kajiwara T, Moriyama N, Narita Y, et al. Silencing of the caspase-1 gene occurs in murine and human renal cancer cells and causes solid tumor growth in vivo. Int J Cancer 2001;91:673-9.
133. Cheson BD, Grever MR. Clinical development of 2deoxycoformycin. In:Cheson BD, Keating MJ, Plunket W, editors. Nucleoside analogs in cancer therapy. New York: Marcel Dekker; 1997. p. 95-112.
134. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: Mechanisms of drug resistance and reveral strategies. Leukemia 2001;15:875-90.
135. Pettitt A. mechanism of action of purine analogues in chronic lymphocytic leukaemia. Br J Hematol 2003;121:692-702.
136. Kawasaki H, Carrera CJ, Piro LD, Saven A, Kipps TJ, Carson DA. Relationship of deoxycytidine kinase and cytoplasmic 5-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood 1993;81:597-601.
137. Seto S, CArrera CJ, Kubota M, Wasson DB, Carson DA. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest 1985;75:377-83.
138. Robertson LE, Chubb S, Meyn RE, Story M, Ford R, Hittelman WN, et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine. Blood 1993;81:143-50.
139. Huang P, Plunkett W. Fludarabine-and gemcitabine-induced apoptosis: Incorporation of analogs into DNA as a critical event. Cancer Chemther Pharmacol 1995;36:181-8.
140. Huang P, Robertson LE, Wright LS, Plunkett W. High molecular weight DNA fragmentation: A critical event in nucleoside analogue-induced apoptosis in leukemia cells. Clin Cancer Res 1995;1:1005-13.
141. Huang P, Ballal K, Plunkett W. Biochemical characterization of the protein activity responsible for high molecular weight DNA fragmentation during drug-induced apoptosis. Cancer Res 1997;57:3407-14.
142. Belosillo B, Dalmau M, Colomer D, Gil J. Involvement of CED-3/ICE proteases in the apoptosis of B-chronic lymphocytic leukemia cells. Blood 1997;89:3378-84.
143. Pettitt AR, Cawley JC. Caspases influence the mode but not the extent of cell death induced by purine analogues in chronic lymphocytic leukaemia. Br J Haematol 2000;109:800-4.
144. Pérez-Galán P, Marzo I, Giraldo P, Rubio-Félix D, Lasierra P, Larrad L, et al. Role of caspases and apoptosis-inducing factor (AIF) in cladribineinduced apoptosis of B cell chronic lymphocytic leukemia. Leukemia 2002;16:2106-14.
145. Sampath D, Plunkett W. The role of c-Jun kinase in the apoptotic response to nucleoside analogue induced DNA damage. Cancer Res 2000;60:6408-15.
146. Achanta G, Pelicano H, Feng L, Plunkett W, Huang P. Interaction of p53 and DNA-PK in response to nucleoside analogues: Potential role as a sensor complex for DNA damage. Cancer Res 2001;61:8723-9.
147. Romano MF, Lamberti A, Turco MC, Venuta S. CD40 and B chronic lymphocytic leukemia cell response to fludarabine: The influence of NF-kappaB/Rel transcription factors on chemotherapy induced apoptosis. Leuk Lymphoma 2000;36:255-62.
148. de la Fuente MT, Casanove B, Moyano JV, Garcia-Gila M, Sanz L, Garcia-Marco J, et al. Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine. J Leukoc Biol 2002;71:495-502.
149. Pepper C, Thomas A, Hidalgo de Quintana J, Davies S, Hoy T, Bentley P. Pleiotropic drug resistance in B-cell chronic lymphocytic leukaemia: The role of Bcl-2 family dysregulation. Leuk Res 1999;23:1007-14.